110997-83-6

Basic information

• Product Name: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
• Synonyms: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
• CAS NO: 110997-83-6
• Molecular Weight: 257.332
• Mol File: 110997-83-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(110997-83-6)
• EPA Substance Registry System: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(110997-83-6)

Safety Data

• Hazardous Substances Data: 110997-83-6(Hazardous Substances Data)

Upstream product

• 56766-90-6 1-(3,4-dimethoxyphenyl)-2-(4-nitrophenyl)ethan-1-one 
• 50434-36-1 4-nitrophenylacetyl chloride 
• 51042-54-7 1,2-Dimethoxy-4-[2-(4-nitrophenyl)ethenyl]benzene 
• 110997-71-2 1,2-dimethoxy-4-[2-(4-nitrophenyl)ethenyl]benzene 
• 104-03-0 4-nitrobenzeneacetic acid 

Downstream Products

• 110998-05-5 N-formyl-4-[2-(3,4-dimethoxyphenyl)ethyl]benzeneamine 
• 110997-07-4 N-[4-[2-(3,4-Dimethoxyphenyl)ethyl]phenyl]-2-hydroxy-4-methylbenzamide 
• 110997-46-1 N-[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]-2-hydroxybenzamide 
• 1670-84-4 1H-indole-2-carboxamide 
• 1186335-59-0 N-{4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl}phthalimide 
• 1186335-65-8 4,5,6,7-tetrachloro-N-{4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl}phthalimide 
• 313676-48-1 2-[[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]amino]benzoic acid 
• 110997-10-9 3-Hydroxy-biphenyl-4-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-67-6 2-Hydroxy-naphthalene-1-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-40-5 1-Hydroxy-naphthalene-2-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-18-7 5-Bromo-N-{4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-2-hydroxy-benzamide 
• 110997-19-8 4-chloro-N-[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]-2-hydroxybenzamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer

A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 μM) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 μM. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC 50 1.7 μM and 0.27 μM, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer.

Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists

Liver X receptor (LXR) α/β dual agonists are candidate medicaments for the treatment of metabolic syndrome, because their biological actions include increasing cholesterol efflux mediated by LXRβ. However, their clinical application is currently limited by their enhancing effect on triglyceride (TG) synthesis mediated by LXRα. Combination of an LXRα-selective antagonist with an LXRα/β dual agonist may overcome this disadvantage. In the present work, structural development studies of phenethylphenyl phthalimide 9, which possesses LXRα/β dual-antagonistic activity and α-glucosidase-inhibitory activity, led to the LXRα-selective antagonist 23f. Specific α-glucosidase inhibitors were also obtained.

Catechol based inhibitors of 15-lipoxygenase

A potent 15-lipoxygenase (15-LO) inhibitor, compound 6, was identified by mass screening the Parke-Davis compound portfolio. The active moiety of compound 6 was determined to be the catechol functionality. Additional analogs were prepared and analyzed for inhibitory activity against 5-, 12-, and 15-lipoxygenase.